



Public Declaration of Interests and Confidentiality Undertaking of European Medicines

Agency (EMA), Scientific Committee members and experts

Public declaration of interests

I, **Nicolino Ruperto**

Organisation/Company: IRCCS G Gaslini

Country: Italy

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment with a Company

No Interest Declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
04/2003-04/2011	Abbott	Adalimumab	Juvenile Idiopathic Arthritis
03/2000-(current)	Centocor Research & Development Inc.	Infliximab, Golimumab	Active Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
12/2008-(current)	Wyeth Pharmaceuticals Inc.	Etanercept, anti CD20	Juvenile Idiopathic Arthritis
07/2003-02/2011	Bristol Myers and Squibb	Abatacept	Juvenile Idiopathic Arthritis
03/2006-(current)	Novartis	Canakinumab	Systemic Juvenile Idiopathic Arthritis
12/2004-(current)	Roche Products	Tocilizumab	Systemic Juvenile Idiopathic Arthritis
04/2009-(current)	Pfizer Inc.	JAK3	Juvenile Idiopathic Arthritis
08/2009-09/2009	Italfarmaco	Givinostat	Systemic Juvenile Idiopathic Arthritis
07/2011-(current)	AstraZeneca	Fostamatinib	Juvenile Idiopathic Arthritis
01/2006-12/2009	"Francesco Angelini" S.P.A.	Paracetamol	Pain associated with pharyngotonsillitis
12/2005-10/2009	Xoma	anti IL1	Juvenile Idiopathic Arthritis
10/2009-(current)	Schwarz Biosciences GmbH	RA0043	Juvenile Idiopathic Arthritis

2.3 Strategic Advisory Role

Period	Company	Products	Therapeutic Indication
--------	---------	----------	------------------------

04/2003-04/2011	Abbott	Adalimumab	Juvenile Idiopathic Arthritis
03/2000-(current)	Centocor Research & Development Inc.	Infliximab, Golimumab	Active Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
12/2008-(current)	Wyeth Pharmaceuticals Inc.	Etanercept, anti CD20	Juvenile Idiopathic Arthritis
07/2003-02/2011	Bristol Myers and Squibb	Abatacept	Juvenile Idiopathic Arthritis
03/2006-(current)	Novartis	Canakinumab	Systemic Juvenile Idiopathic Arthritis
12/2004-(current)	Roche Products	Tocilizumab	Systemic Juvenile Idiopathic Arthritis
04/2009-(current)	Pfizer Inc.	JAK3	Juvenile Idiopathic Arthritis
08/2009-09/2009	Italfarmaco	Givinostat	Systemic Juvenile Idiopathic Arthritis
07/2011-(current)	AstraZeneca	Fostamatinib	Juvenile Idiopathic Arthritis
01/2006-12/2009	"Francesco Angelini" S.P.A.	Paracetamol	Pain associated with pharyngotonsillitis
12/2005-10/2009	Xoma	anti IL1	Juvenile Idiopathic Arthritis
10/2009-(current)	Schwarz Biosciences GmbH	RA0043	Juvenile Idiopathic Arthritis

2.4 Current Financial Interests

Company	Financial Interest
AstraZeneca	honoraria for meeting presentation/attendance
Novartis	honoraria for meeting presentation/attendance
Bristol-Myers and Squibb	honoraria for meeting presentation/attendance
Roche	honoraria for meeting presentation/attendance

2.5 Patent

No Interest Declared

2.6 Principal Investigator

Period	Company	Products	Therapeutic Indication
01/2006-12/2009	"Francesco Angelini" S.P.A.	Paracetamol	Pain associated with pharyngotonsillitis
03/2000-07/2008	Centocor	Infliximab	Juvenile Idiopathic Arthritis
03/2006-(current)	Novartis	Canakinumab	Systemic Juvenile Idiopathic Arthritis

2.7 Investigator

Period	Company	Products	Therapeutic Indication
04/2003-04/2011	Abbott	Adalimumab	Juvenile Idiopathic Arthritis
03/2000-07/2008	Centocor Research & Development Inc.	Infliximab	Active Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
03/2006-(current)	Novartis	Canakinumab	Systemic Juvenile Idiopathic Arthritis
12/2004-(current)	Roche Products	Tocilizumab	Systemic Juvenile Idiopathic Arthritis

2.8 Grant / Funding to Institution

Company	Subject Matter
Abbott	consultancy
Centocor Research & Development	consultancy
Wyeth Pharmaceuticals Inc.	consultancy
Bristol Myers and Squibb	consultancy
Novartis	consultancy
Roche Products	consultancy
Pfizer Inc.	consultancy
Italfarmaco	consultancy
AstraZeneca	consultancy
"Francesco Angelini" S.P.A.	consultancy
Xoma	consultancy
Swartz Biosciences GmbH	consultancy

2.9 Family Member Interest

No Interest Declared

Other Interests or Facts

I declare that the funding received from consultancies or services provided to the pharmaceutical companies listed at point 2.2, 2.3, 2.6, 2.7, 2.8 are transferred to the Hospital Gaslini banking details and not to my personal account with the exception of honoraria listed in section 2.4

SECTION 3: CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.

- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I consent to my information being stored electronically and published on the EMA website.

Full Name:	Nicolino Ruperto
Date:	2012-06-25

For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template